Rx and therapeutics
ODS is committed to bringing to you, its partners, the very latest information on the availability of new prescription drugs, medication safety information and drug recalls.
Prescription drug updates 2012
February
Prescription drug updates 2011
September
July
- Chantix (varenicline): Label Change - Risk of Certain Cardiovascular Adverse Events
- FDA Drug Safety Communication: Ongoing review of Avandia (rosiglitazone) and cardiovascular safety
June
- Risperdal and Risperidone Recall
- FDA Announces Safety Recommendations for High-Dose Simvastatin
- Birth Control Pills Containing Drospirenone: Possible Increased Risk of Blood Clots
May
April
March
Prescription drug updates 2010
November
October
September
August
July
- Arava (leflunomide): Boxed Warning - Risk of Severe Liver Injury
- Angiotensin Receptor Blockers (ARBs): Ongoing Safety Review for Cancer Risk
June
- Orlistat (marketed as Alli and Xenical): Labeling Change
- FDA Warns of Suicide Risk for Tramadol
- Benicar (olmesartan): Ongoing Safety Review
- Mylotarg (gemtuzumab ozogamicin): Market Withdrawal
- Re-Post: FDA Drug Safety Communication: Ongoing review of Avandia (rosiglitazone) and cardiovascular safety
May
- FDA Approves New Combination Product Oral Contraceptive
- Proton Pump Inhibitors (PPI): Class Labeling Change
April
- Zocor (simvastatin): increased risk of muscle injury with high doses
- Generic Losartan and Losartan Potassium/Hydrochlorothiazide Tablets Approved
- Propylthiouracil Boxed Warning
March
- Aldara Generic Imiquimod Cream Approved
- Takeda renames heartburn drug to avoid errors
- Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures
- Plavix (clopidogrel): Reduced effectiveness in patients who are poor metabolizers of the drug
February
Log in to Benefit Tracker
Check benefits and eligibility
Log in to Benefit Tracker
Check benefits and eligibility
Shopping for health insurance?
Shopping for health insurance?
